Journal of the American Society of Nephrology, Vol 7, 543-549, Copyright © 1996 by American Society of Nephrology

REGULAR ARTICLES

Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis

MJ Gregory, WE Smoyer, A Sedman, DB Kershaw, RP Valentini, K Johnson and TE Bunchman
Department of Pediatrics, University of Michigan, Ann Arbor, USA.

Cyclosporine (CsA) is effective in treating steroid-dependent (SDNS) and steroid-resistant (SRNS) nephrotic syndrome (NS) in children, but because of the potential for chronic nephrotoxicity, its long-term use is controversial. This study reports the results of long-term CsA treatment in 22 children with idiopathic NS. Indications for treatment included SDNS (N = 7) and SRNS (N = 15) children. Pre-CsA histology showed minimal change disease in three patients, immunoglobulin M nephropathy (IgM) in 14 patients, and focal segmental glomerulosclerosis (FSGS) in five patients. All patients had normal initial serum creatinine values. CsA was added to prednisone at 6.3 +/- 0.4 mg/kg per day (mean +/- SE) and adjusted to maintain whole blood trough HPLC levels of 70 to 120 ng/mL for a period of 6 to 53 months (mean, 22 months). Analysis by clinical course revealed that 13 of 15 patients with SRNS (87%) entered remission after a mean duration of CsA treatment of 58 days, whereas seven of seven patients with SDNS were able to be weaned off of daily prednisone therapy. Histologic analysis showed that all five patients with FSGS and 13 of 14 patients with IgM nephropathy either entered remission or were weaned off of daily steroids. Ten of the 22 patients (45%) with complete remission required CsA plus low-dose alternate-day prednisone to maintain remission. Hypertension was seen in eight of 22 patients (36%). No patient had a significant increase in serum creatinine concentration. Renal biopsies performed in 12 patients after 12 to 41 months (mean, 21 months) of CsA therapy showed no nephrotoxicity or disease progression in ten patients. Progression of the previous interstitial fibrosis and tubular atrophy was noted in two patients, suggesting a 17% incidence of CsA nephrotoxicity. This analysis of the long-term risks and benefits of CsA for childhood NS has identified two important findings: (1) combined CsA and alternate-day steroids can be highly effective in inducing complete remission in patients with SRNS and biopsy-proven IgM nephropathy, and (2) long-term use of CsA in moderate doses with closely monitored levels can result in a relatively low incidence of nephrotoxicity.

This article has been cited by other articles:

				J. H. H. Ehrich, C. Geerlings, M. Zivicnjak, D. Franke, H. Geerlings, and J. Gellermann Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2183 - 2193. [Abstract] [Full Text] [PDF]

				S Fujinaga, K Kaneko, T Muto, Y Ohtomo, H Murakami, and Y Yamashiro Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome Arch. Dis. Child., August 1, 2006; 91(8): 666 - 670. [Abstract] [Full Text] [PDF]

				J. A. Tumlin, D. Miller, M. Near, S. Selvaraj, R. Hennigar, and A. Guasch A Prospective, Open-Label Trial of Sirolimus in the Treatment of Focal Segmental Glomerulosclerosis Clin. J. Am. Soc. Nephrol., January 1, 2006; 1(1): 109 - 116. [Abstract] [Full Text] [PDF]

				Y. Kawasaki, M. Hosoya, S. Kobayashi, S. Ohara, N. Onishi, A. Takahashi, M. Isome, and H. Suzuki Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2243 - 2247. [Abstract] [Full Text] [PDF]

				G. Filler How should microemulsified Cyclosporine A (Neoral(R)) therapy in patients with nephrotic syndrome be monitored? Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1032 - 1034. [Full Text] [PDF]

				A. El-Husseini, F. El-Basuony, A. Donia, I. Mahmoud, N. Hassan, N. Sayed-Ahmad, and M. Sobh Concomitant administration of cyclosporine and ketoconazole in idiopathic nephrotic syndrome Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2266 - 2271. [Abstract] [Full Text] [PDF]

				A. L. Friedman Treatment of Minimal Change Nephrotic Syndrome with Cyclosporin AAP Grand Rounds, December 1, 2002; 8(6): 69 - 70. [Full Text] [PDF]

				K. IIJIMA, K. HAMAHIRA, A. KOBAYASHI, H. NAKAMURA, and N. YOSHIKAWA Immunohistochemical Analysis of Renin Activity in Chronic Cyclosporine Nephropathy in Childhood Nephrotic Syndrome J. Am. Soc. Nephrol., December 1, 2000; 11(12): 2265 - 2271. [Abstract] [Full Text]

				R. J. Hogg, R. J. Portman, D. Milliner, K. V. Lemley, A. Eddy, and J. Ingelfinger Evaluation and Management of Proteinuria and Nephrotic Syndrome in Children: Recommendations From a Pediatric Nephrology Panel Established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE) Pediatrics, June 1, 2000; 105(6): 1242 - 1249. [Abstract] [Full Text]

				S. R. Orth and E. Ritz The Nephrotic Syndrome N. Engl. J. Med., April 23, 1998; 338(17): 1202 - 1211. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673